Transasia continues its run in the
international markets. The company entered the US, Italy and Turkish
markets in FY 2010-11
of diagnostic instruments
Transasia House, 8 Chandivali Studio Road,
Mumbai - 400072
Mumbai-based Transasia Bio-Medicals Limited, a
manufacturer and exporter of diagnostic instruments in India, witnessed
a growth of 88 percent in 2010-11 by generating total sales revenue of
350 crore as compared to
186 crore in 2009-10. Transasia has
40 percent market in the haematology segment and is looking to enlarge
its market share in several segments including oncology, diabetes,
cardiovascular and infectious diseases.
The company has a 32-year track record in the industry and has
successfully developed and manufactured hi-tech in vitro diagnostic
(IVD) instruments and reagents. Started in 1979 as a marketing firm for
a few imported diagnostic equipments, Transasia today has over 30,000
installations, supported by a network of 65 service centers and zonal
offices spread across all the major cities. Fiscal 2010-2011, saw some
eye-catching developments within the company’s strategy, both in terms
of market expansion and increase in its product basket. Says Mr Suresh
Vazirani, CMD, Transasia Bio-Medicals, “We have expanded into
international markets, where there is a potential for growth. We have
made an entry in the US, Italy and Turkish market this year, after our
entry in Czech Republic and Russia in the last year.”
In order to boost its product basket, Transasia is looking at striking
alliances with leading diagnostic companies in the world. Today, it has
three manufacturing facilities in India, one each in Germany, Czech
Republic, Italy and US.
On Jan 14, 2011, Erba Diagnostics Mannheim GmbH, a 100 percent
Germany-based subsidiary of Transasia, acquired a 100 percent stake in
Diasis Diagnostik Sistemler Ticaret Ve Sanayi A S, Istanbul, Turkey.
Diasis is an ISO 9001/2000 and ISO 13485/2003 certified company that is
involved in the development, production and marketing of products for
IVD in the field of biochemistry, haematology and urine analysis.
Transasia, with the help of Erba Diagnostics, also acquired a majority
stake in a US-based IVD company, Ivax Diagnostics. Ivax is a fully
integrated in vitro diagnostics company that develops, manufactures and
distributes proprietary diagnostic reagents, test kits and
instrumentation for autoimmune and infectious diseases, in the US
and other international markets.
Transasia also has an alliance called the Sysmex Network Communication
System (SNCS), an internet based online customer service launched in
colloboration with Sysmex.
The company now has major expansion plans up its sleeve. “If the IVD
market continues to grow at 12-15 percent, we are looking at a growth
rate of 30-40 percent year-on-year. We will see five-to-10 product
launches this year in 2011,” says Dr Gurumukh Advani, president, sales
and marketing. While small labs and government labs have been the main
focus until date, the company is now looking at extending its products
to corporate hospitals, CROs and chain laboratories. The company is
also looking to scale up its infrastructure in several locations in
India, including Mumbai, Baddi (Himachal Pradesh) and Daman.